Back to Journals » Therapeutics and Clinical Risk Management » Call For Papers

PubMed
SJR OA
CiteScore
Impact Factor

Therapeutics and Clinical Risk Management

COPE logo
ISSN: 1178-203X

The following Article Collection/ Thematic Series is currently open for submissions:

We are pleased to announce a new Article Collection in Therapeutics and Clinical Risk Management, dedicated to the role of biologic treatments in the management of allergic disease. Since their clinical introduction, biologic treatments, particularly monoclonal antibodies, have transformed patient care, offering targeted therapies and improved outcomes for conditions including allergic asthma, allergic rhinitis, atopic dermatitis and urticaria.

Given the importance of biologics in managing allergic disease, we are welcoming submissions of original research articles, reviews, and perspectives exploring the mechanisms of action, clinical efficacy, safety, and real-world application of these therapies.

The Collection, edited by the Editor-In-Chief Prof. Garry Walsh, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, drugs, or technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes. Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

While the call is open to receive manuscripts across the broad spectrum of biologic treatments in allergic disease, the Editors are particularly interested in manuscripts relating to the following areas:
• Mechanisms of action and biomarkers for personalized treatment
• Clinical efficacy and safety profiles
• Real-world evidence and patient-reported outcomes
• Cost-effectiveness and health economic evaluations
• Reviews, perspectives and editorials discussing emerging therapies and future directions

All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code 7A889 to indicate that your submission is for consideration in this Article Collection.

The deadline for submitting manuscripts is 1 April 2026.

If you have any queries regarding the Article Collection or would like to discuss a submission, then please email the Commissioning Editor, Catherine Teng at [email protected].

View all papers in this article collection

Call For Papers

Journal Image

Editor-in-Chief: Professor Garry Walsh


To see where Therapeutics and Clinical Risk Management is indexed online view the Journal Metrics

What is the advantage to you of publishing in Therapeutics and Clinical Risk Management?

  • It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove website.
  • Although Therapeutics and Clinical Risk Management receives a large number of papers, unlike many traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish.
  • The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors. Therapeutics and Clinical Risk Management has a quicker turnaround time than this. Generally peer review is complete within 3-4 weeks and the editor’s decision within 2-14 days of this. It is therefore very rare to have to wait more than 6 weeks for first editorial decision.
  • Many authors have found that our peer reviewer’s comments substantially add to their final papers.

To recover our editorial and production costs and continue to provide our content at no cost to readers we charge authors or their institution an article publishing charge.

PubMed Central
Therapeutics and Clinical Risk Management is indexed on PubMed Central (title abbreviation: Ther Clin Risk Manag).  All published papers in this journal are submitted to PubMed for indexing straight away.

Become a Favored Author and receive real benefits
If you haven't already joined the Dove Press Favored Author Program I would encourage you to do so. Why? To receive real benefits like fast-tracking and a personal co-ordinator for your paper, as well as a discount on the publication processing fee.
Click here to go through to the Favored Author signup page.

Yours sincerely
Professor Garry Walsh
Editor-in-Chief
Therapeutics and Clinical Risk Management

Email: Editor-in-Chief

Updated 11 October 2022

Related journals you may also be interested in: